The Bengaluru police have launched a probe into a cyber fraud case where hackers allegedly infiltrated the official email communication between city-based Group Pharmaceuticals and Dr Reddy's Laboratories, Hyderabad, successfully diverting a payment of Rs 2.16 crore to a fraudulent account.
Dr Reddy's Laboratories has received approval from Health Canada to sell a generic version of the diabetes drug semaglutide, making it the first company to get market authorisation for a generic semaglutide injection in Canada and the first in a G7 country.
Shares of Dr Reddy's Laboratories jumped 5.3 per cent on Thursday to Rs 1,217 apiece, making it the top gainer in the Nifty 50 and the BSE 100 indices. By comparison, the Nifty 50 was up 0.53 per cent at 25,289.
At the heart of this debate is Section 3(d) of the Patents Act, a safeguard designed to prevent drugmakers from extending monopoly protection through trivial modifications to existing medicines.
Pharma major Dr Reddy's Laboratories (DRL) reported a 14 per cent year-on-year (Y-o-Y) drop in consolidated net profit to Rs 1,210 crore in the December quarter of FY 2025-26 (Q3FY26) on low sales of cancer drug Lenalidomide in the North American market. The firm's revenue from operations grew to Rs 8,727 crore in Q3FY26, a 4.4 per cent Y-o-Y increase from Rs 8,357 crore recorded for the same quarter last year.
A TDP MP and former BRS MLA are among six people detained in Hyderabad after testing positive for drug consumption following a raid on a farmhouse party.
A drug raid at a Hyderabad farmhouse led to the detention of a TDP MP and a former BRS MLA, sparking a police investigation into drug consumption and illegal activities.
A TDP MP and former BRS MLA were among those detained after a drug raid at a farmhouse in Moinabad, Hyderabad. Some individuals tested positive for drug consumption, and a businessman was detained for allegedly firing a weapon.
A TDP MP and former BRS MLA were among those detained following a drug bust at a farmhouse in Moinabad near Hyderabad. Some individuals tested positive for drug consumption, and a businessman was arrested for allegedly firing a weapon.
Equity market investors would track global trends, foreign fund movement and quarterly earnings in a holiday-shortened week ahead, analysts said. Stock exchanges BSE and NSE will conduct a special Muhurat trading session on Tuesday, October 21.
Buoyant domestic sales are expected to lift revenues for pharma companies by 8-11 per cent in Q3FY26, even as declining generic Revlimid (cancer drug) sales in the US remain a key drag. Most brokerages forecast a modest 2-4 per cent growth in profit after tax (PAT) for the quarter. Hospitals and diagnostics companies, meanwhile, are likely to post much stronger numbers, with revenues seen growing 20-22 per cent year-on-year (Y-o-Y).
Karnataka Home Minister G Parameshwara said preliminary reports indicate the bullet that killed a person in Ballari clashes was likely fired from a private weapon, not police firearms. A high-level probe has been ordered into the incident.
For decades, multinational pharmaceutical companies and Indian drugmakers worked in ways that supported each other: MNCs brought innovation and brands, while Indian companies built scale through generics and cost efficiency. There was an important overlap - generic drugs - but this is shrinking fast. And the consequences are reshaping India's gigantic pharmaceutical market.
'As more patients are prescribed these drugs, intolerance due to gastrointestinal and other side effects will become more visible, leading to higher discontinuation rates.'
Despite being a doctor, Mahendra allegedly did not perform CPR. She was taken to a nearby hospital, where doctors declared her dead on arrival, Muni Reddy alleged. Postmortem and Forensic Science Laboratory (FSL) reports later confirmed the presence of anaesthetic substances in her organs, police said.
Dr Reddy's Laboratories (DRL) share price plunged 6.66 per cent to Rs 1,203.50 per share on the NSE during Friday after analysts remained cautious on the company's Q3 performance and differed on its growth outlook. DRL's Q3 performance was viewed as subdued by some analysts when they adjusted it for one-time grants and incomes that the company received during the quarter.
Pharma major Dr Reddy's Laboratories delivered a muted operational performance in the fourth quarter of financial year 2024-25 (Q4FY25), even as revenue growth remained healthy. Lower gross margin performance and muted domestic growth are key concerns. Most brokerages have a "Sell" or "Reduce" rating as there are uncertainties related to the development of a new product portfolio and the launch timelines.
Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines.
'Our problem is not a budget deficit but a trust deficit. We need to trust our institutions and industries to innovate and lead. That is the way forward for India.'
On December 27 last year, Pfizer had moved to the US District Court for the District of Delaware against Dr Reddy's Laboratories Ltd and Dr Reddy's Laboratories Inc for infringement of Pfizer's crystalline atorvastatin patent.
Trading sentiment in the stock market this week will be guided by quarterly earning announcements from blue-chips such as Infosys and Bajaj Finance, the outcome of India-US trade talks and global cues, analysts said. Markets may on Monday react to the quarterly results of three heavyweights - Reliance Industries, HDFC Bank and ICICI Bank, an expert said.
Kejriwal's announcement came after Deputy Chief Minister Manish Sisodia earlier this week claimed that Covaxin manufacturer Bharat Biotech has refused to provide additional doses to the national capital.
The company will supply the drug to major government as well as private hospitals across India, Dr Reddy's said in a regulatory filing.
Pharma major Dr Reddy's Laboratories has opposed the parliamentary Standing committee's recommendations of increasing the number of drugs under price control and cap on profit margins of all medicines.
The Russian Direct Investment Fund (RDIF) and Dr Reddy's Laboratories have agreed to cooperate on clinical trials and distribution of Sputnik V vaccine in India, RDIF and Dr Reddy's said in a joint statement.
Dr. K. Anji Reddy, Founder and Chairman of Dr. Reddy's Laboratories, died at a hospital in Hyderabad on Friday. He was 72.
The patent relates to the manufacturing process for the active ingredient in Sanofi-Aventis' Allegra and Allegra-D drug products. Both Dr Reddys and Sandoz are known to be marketing these products in the US.
Avigan comes in a complete therapy pack of 122 tablets with a two-year shelf life.
The US Food and Drug Administration's (USFDA)'s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars - lower-priced, near-replicas of complex biologic medicines - could significantly benefit Indian biotech companies.
The transaction is expected to be closed in the first quarter of the financial year.
Concerns over weakening demand for Indian pharmaceutical (pharma) drugs in the US - their largest export market - have weighed heavily on investor sentiment this year. While the Nifty 50 has gained 6.02 per cent year - to - date (as on September 15), the Nifty Pharma index has declined 5.18 per cent, National Stock Exchange data shows.
Dr Reddy's Laboratories on Friday soft-launched imported COVID-19 vaccine Sputnik V, with Deepak Sapra, a senior executive of the drug-maker, taking the first shot in Hyderabad.
Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.
Dr Reddy's, which has tied up with Russian Direct Investment Fund for Sputnik V in India, soft launched the vaccine in India in May 2021, after receiving Emergency Use Authorisation in April 2021.
India's generic drug manufacturer, Dr Reddy's Laboratories, suffered a setback when a US' Court of Appeals ruled that it infringed on Pfizer Pharmaceutical company's patent for the blood pressure medicine Norvasc.
Dr Reddys Laboratories Ltd and Leiner Health Products signed a 15-year product development and marketing agreement for for Dr Reddys over-the-counter drug products.
The Hyderabad-based drugmaker said consolidated net profit rose to Rs Rs 361 crore (Rs 3.61 billion) for the fiscal first quarter ended June, from Rs 336 crore (Rs 3.36 billion) a year earlier.
Dr Reddy's Laboratories on Saturday reported a 93.79 per cent increase in consolidated net profit at Rs 90.91 crore (Rs 909.1 million) for the second quarter ended September 30, 2005
